A5862

Manufactured by Merck Group

Sourced in Germany

The A5862 is a laboratory equipment product manufactured by Merck Group. It serves as a core apparatus for various scientific applications. The product's primary function is to perform specific tasks within the controlled environment of a laboratory setting. No further details are provided to maintain an unbiased and factual approach.

Automatically generated - may contain errors

Lab products found in correlation

Cycloheximide (chx), by Merck Group (1 mentions) P9620, by Merck Group (1 mentions) E2375, by Merck Group (1 mentions) Sml1091, by Merck Group (1 mentions) Anisomycin, by Merck Group (1 mentions) Mabe343, by Merck Group (1 mentions) Ant pr 1, by InvivoGen (1 mentions) Puromycin, by Merck Group (1 mentions)

2 protocols using a5862

Sourcing and Handling Chemical Compounds

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following compounds were obtained from Sigma: CHX (100 mg/mL stock in DMSO; C1988), PURO (10 mg/mL stock in water; P9620), ANS (10 mg/mL stock in DMSO; A5862), EME (100 mg/mL stock in water; E2375), and HHT (10 mg/mL stock in DMSO; SML1091). LTM (5 mM stock in DMSO; 506291) was obtained from Millipore. BVD (10 mM stock in DMSO) and DIDB (10 mM in DMSO) were kind gifts from Tin Tin Su (University of Colorado at Boulder) and Malia Potts (St. Jude Children's Research Hospital), respectively. NSC119893 (50 mM stock in DMSO) was obtained from the National Cancer Institute Development Therapeutics Program.

Kearse M.G., Goldman D.H., Choi J., Nwaezeapu C., Liang D., Green K.M., Goldstrohm A.C., Todd P.K., Green R, & Wilusz J.E. (2019). Ribosome queuing enables non-AUG translation to be resistant to multiple protein synthesis inhibitors. Genes & Development, 33(13-14), 871-885.

+ Open protocol

+ Expand

Puromycin Labeling of Nascent Proteins

Check if the same lab product or an alternative is used in the 5 most similar protocols

1 µg/ml of puromycin (ant-pr-1, InvivoGen, US) was added into the cultures. After 10 min of incubation, coverslips were washed with Tyrode buffer. The fixation was followed with 4% PFA. Anisomycin (0.13 μM, A5862, Sigma-Aldrich, Germany) was used in order to detect the background signal of the assay. For the control group, it was added 10 min before the actual puromycin treatment. After the fixation, cells were immunostained, as described in the immunostaining section, against Synaptophysin (101004, Synaptic Systems, Germany), Homer1 (160011, Synaptic Systems, Germany), and puromycin (MABE343, Merck Millipore, Germany).

Sertel S.M., Blumenstein W., Mandad S., Shomroni O., Salinas G, & Rizzoli S.O. (2021). Differences in synaptic vesicle pool behavior between male and female hippocampal cultured neurons. Scientific Reports, 11, 17374.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!